Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.53 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.48 |
| ▸ | GRM1 | Q13255 | 11/20 | 0.46 |
| ▸ | GRM5 | P41594 | 11/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.46 |
| ▸ | CDK7 | P50613 | 1/20 | 0.43 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.43 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | BTK | Q06187 | 1/20 | 0.42 |
| ▸ | KIT | P10721 | 1/20 | 0.42 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL349200 | 0.82 | NAMPT (0.54) | NAMPTPDK4GRM1GRM5CYP11B2 | |
| SCHEMBL1554789 | 0.81 | NAMPT (0.58) | NAMPTPDK4GRM1GRM5CYP11B2 | |
| SCHEMBL578028 | 0.81 | NAMPT (0.60) | NAMPTPDK4GRM1GRM5CYP11B2 | |
| SCHEMBL8912847 | 0.81 | NAMPT (0.63) | NAMPTPDK4GRM1GRM5CYP11B2 | |
| SCHEMBL904049 | 0.80 | NAMPT (0.61) | NAMPTPDK4GRM1GRM5CYP11B2 | |
| SCHEMBL30726399 | 0.79 | NAMPT (0.49) | NAMPTPDK4GRM1GRM5CYP11B2 | |
| SCHEMBL18619842 | 0.78 | NAMPT (0.60) | NAMPTPDK4GRM1GRM5CYP11B2 | |
| SCHEMBL2908091 | 0.78 | NAMPT (0.60) | NAMPTPDK4GRM1GRM5CYP11B2 | |
| SCHEMBL29227506 | 0.78 | NAMPT (0.60) | NAMPTPDK4GRM1GRM5CYP11B2 | |
| SCHEMBL2594283 | 0.78 | GRM1 (0.65) | NAMPTPDK4GRM1GRM5KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9957229-B2 | Amido compounds and their use as pharmaceuticals | INCYTE HOLDINGS CORPORATION (US) | 2018-05-01 | — | — | US | disclosed |
| US-20170334847-A1 | Amido Compounds And Their Use As Pharmaceuticals | INCYTE CORPORATION | 2017-11-23 | — | — | US | disclosed |
| US-9670154-B2 | Amido compounds and their use as pharmaceuticals | INCYTE HOLDINGS CORPORATION (US) | 2017-06-06 | — | — | US | disclosed |
| EP-2963021-A1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | Incyte Holdings Corporation (US) | 2016-01-06 | — | — | EP | disclosed |
| US-20150329561-A1 | Amido Compounds And Their Use As Pharmaceuticals | INCYTE CORPORATION | 2015-11-19 | — | — | US | disclosed |
| US-9126927-B2 | Amido compounds and their use as pharmaceuticals | INCYTE HOLDINGS CORPORATION (US) | 2015-09-08 | — | — | US | disclosed |
| EP-1756063-B1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2015-07-08 | — | — | EP | disclosed |
| US-20120015928-A1 | Amido Compounds And Their Use As Pharmaceuticals | INCYTE CORPORATION (US) | 2012-01-19 | — | — | US | disclosed |
| US-8058288-B2 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2011-11-15 | — | — | US | disclosed |
| US-20100256114-A1 | Amido Compounds And Their Use As Pharmaceuticals | INCYTE CORPORATION (US) | 2010-10-07 | — | — | US | disclosed |
| US-7776874-B2 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2010-08-17 | — | — | US | disclosed |
| EP-1756063-A4 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2009-03-25 | — | — | EP | disclosed |
| US-20080255154-A1 | Cycloalkylcarbonyl-3H-spiro[2-benzofuran-1,3'-pyrrolidin]-3-ones: N-methyl-5-[4-(1-{[3-oxo-1'H,3H-spiro[2-benzofuran-1,3'-pyrrolidin]-1'-yl]carbonyl}cyclopropyl)phenyl]pyridine-2-carboxamide; 11- beta hydroxyl steroid dehydrogenase type 1 inhibitors; mineralcorticoid receptor antagonists; diabetes | INCYTE CORPORATION (US) | 2008-10-16 | — | — | US | disclosed |
| US-7304081-B2 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2007-12-04 | — | — | US | disclosed |
| US-20070179142-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2007-08-02 | — | — | US | disclosed |
| EP-1756063-A1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | Incyte Corporation (US) | 2007-02-28 | — | — | EP | disclosed |
| US-20050282858-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2005-12-22 | — | — | US | disclosed |
| WO-2005110992-A1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2005-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334847-A1 | Amido Compounds And Their Use As Pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | NAMPT 1291/4885PDK4 771/4885GRM1 353/4885 |
| US-20100256114-A1 | Amido Compounds And Their Use As Pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | NAMPT 1291/4885PDK4 771/4885GRM1 353/4885 |
| US-20050282858-A1 | Amido compounds and their use as pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | NAMPT 1291/4885PDK4 771/4885GRM1 353/4885 |
| US-20120015928-A1 | Amido Compounds And Their Use As Pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | NAMPT 1291/4885PDK4 771/4885GRM1 353/4885 |
| US-20080255154-A1 | Cycloalkylcarbonyl-3H-spiro[2-benzofuran-1,3'-pyrrolidin]-3-ones: N-methyl-5-[4-(1-{[3-oxo-1'H,3H-spiro[2-benzofuran-1,3'-pyrrolidin]-1'-yl]carbonyl}cyclopropyl)phenyl]pyridine-2-carboxamide; 11- beta hydroxyl steroid dehydrogenase type 1 inhibitors; mineralcorticoid receptor antagonists; diabetes | HSD11B1, NR3C2, SRD5A1 | NAMPT 735/4885PDK4 160/4885GRM1 563/4885 |
| US-20150329561-A1 | Amido Compounds And Their Use As Pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | NAMPT 1291/4885PDK4 771/4885GRM1 353/4885 |
| US-20070179142-A1 | Amido compounds and their use as pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | NAMPT 1291/4885PDK4 771/4885GRM1 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.